• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13E3/A filed by Eargo Inc. (Amendment)

    2/16/24 9:58:49 AM ET
    $EAR
    Medical Specialities
    Health Care
    Get the next $EAR alert in real time by email
    SC 13E3/A 1 ny20021593x1_sc13e3a.htm SC 13E3/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13E-3
    (Amendment No. 4)

    RULE 13E-3 TRANSACTION STATEMENT UNDER
    SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934


    Eargo, Inc.
    (Name of the Issuer)


    Eargo, Inc.
    PSC Echo Parent LLC,
    PSC Echo Merger Sub Inc.,
    PSC Echo, LP,
    PSC Echo GP, LLC
    (Names of Persons Filing Statement)
    Common Stock, Par Value $0.0001 per share
    (Title of Class of Securities)
    Common Stock: 270087109
    (CUSIP Number of Class of Securities)​



    William Brownie
    Interim Chief Executive Officer and Chief Operating Officer
    Eargo, Inc.
    2665 North First Street, Suite 300
    San Jose, California 95134
    (650) 351-7700
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Persons Filing Statement)​


      
    With copies to
    Jason Freedman
    Walton Dumas
    Ropes & Gray LLP
    Three Embarcadero Center
    San Francisco, CA 94111
    (415) 315-6300
    Tom Fraser
    Ropes & Gray LLP
    Prudential Tower
    800 Boylston Street
    Boston, MA 02199
    (617) 951-7000
    Oliver Smith
    Michael Gilson
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, NY 10017
    (212) 450-4000

    This statement is filed in connection with (check the appropriate box):

    a.
    ☐
    The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
    b.
    ☐
    The filing of a registration statement under the Securities Act of 1933.
    c.
    ☐
    A tender offer.
    d.
    ☒
    None of the above.

    Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☐

    Check the following box if the filing is a final amendment reporting the results of the transaction: ☒

    ​INTRODUCTION
    This Amendment No. 4 (this “Final Amendment”) to the Rule 13E-3 Transaction Statement on Schedule 13E-3, together with the exhibits hereto (as amended hereby, this “Schedule 13E-3” or “Transaction Statement”), is being filed with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), jointly by the following persons (each, a “Filing Person,” and collectively, the “Filing Persons”): (i) Eargo, Inc. (“Eargo” or the “Company”), a Delaware corporation and the issuer of the common stock, par value $0.0001 per share (the “Shares”), that is subject to the Rule 13e-3 transaction, (ii) PSC Echo Parent LLC, a Delaware limited liability company (“Parent”), (iii) PSC Echo Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), (iv) PSC Echo, LP, a Delaware limited partnership and sole member of Parent (“PSC Echo”) and (v) PSC Echo GP, LLC, a Delaware limited liability company and general partner of PSC Echo (“PSC Echo GP”). Parent, Merger Sub, PSC Echo and PSC Echo GP are Filing Persons of this Transaction Statement because they are affiliates of the Company under the SEC rules governing “going-private” transactions.
    This Transaction Statement relates to the Agreement and Plan of Merger, dated October 29, 2023, by and among the Company, Parent and Merger Sub (as amended, restated, supplemented or otherwise modified from time to time, the “Merger Agreement”), pursuant to which, and on the terms set forth therein, Merger Sub has merged with and into the Company, with the Company as the surviving corporation (the “Merger”).

    Pursuant to General Instruction F to Schedule 13E-3, the information contained in the Company’s definitive proxy statement, dated January 16, 2024 (the “Definitive Proxy Statement”), including all appendices thereto, is incorporated in its entirety herein by reference, and the responses to each item in this Schedule 13E-3 are qualified in their entirety by the information contained in the Definitive Proxy Statement and the appendices thereto.

    Capitalized terms used but not expressly defined in this Final Amendment shall have the respective meanings given to them in the Definitive Proxy Statement.

    This Final Amendment is being filed pursuant to Rule 13E-3(d)(3) under the Exchange Act to report the results of the transaction that is the subject of this Transaction Statement. Except as otherwise set forth below, the information set forth in the Schedule 13E-3 remains unchanged. This Final Amendment is being filed to reflect certain updates as reflected below.
    Item 15.   Additional Information 
    (c)   Other Material Information.   The information set forth in response to Item 1011(c) of Regulation M-A is hereby amended and supplemented as follows:

    On February 13, 2024, at the Special Meeting, Eargo’s stockholders voted to (i) approve the Merger Agreement Proposal, (ii) approve the Golden Parachute Proposal and (iii) approve the Adjournment Proposal.
    ​
    All three proposals were approved by the requisite vote of the Company’s stockholders, including the Merger Agreement Proposal, which was approved by the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Company Common Stock entitled to vote in accordance with the DGCL. Each record holder of Company Common Stock was entitled one (1) vote for each outstanding share of Company Common Stock owned of record on the Record Date.

    On February 16, 2024, the parties filed a Certificate of Merger with the Office of the Secretary of State of the State of Delaware, pursuant to which the Merger became effective and Merger Sub was merged with and into Eargo, with Eargo continuing as the surviving corporation in the Merger. As a result of the Merger, Eargo became a wholly owned subsidiary of the PSC Stockholder.

    At the effective time of the Merger (the “Effective Time”), each share of Company Common Stock issued and outstanding immediately prior to the Effective Time, other than certain excluded Shares pursuant to the terms of the Merger Agreement, were cancelled and extinguished and automatically converted into and thereafter represent the right to receive an amount in cash equal to $2.55 per Share, payable to the holder thereof, without interest, subject to and in accordance with the terms and conditions of the Merger Agreement.

    As a result of the Merger, shares of Company Common Stock have ceased to trade on Nasdaq and became eligible for delisting from Nasdaq and termination of registration under the Exchange Act. Nasdaq has filed with the SEC a notification of removal from listing on Form 25 with respect to the delisting of Company Common Stock and deregistration under Section 12(b) of the Exchange Act. Eargo intends to file with the SEC a certification on Form 15 to deregister the shares of Company Common Stock under Section 12(g) of the Exchange Act and terminate or suspend its reporting obligations under Sections 13(a) and 15(d) of the Exchange Act.

    On February 16, 2024, Eargo and the PSC Stockholder issued a joint press release announcing the closing of the Merger. The press release is attached as Exhibit 99.1 to a Form 8-K filed by Eargo on February 16, 2024 and is incorporated by reference herein as Exhibit (a)(3).

    Item 16.   Exhibits

    The following exhibits are filed herewith:

    Exhibit No.
    ​
    ​
    Description
    (a)(2)(i)
    ​
    ​
    Definitive Proxy Statement of Eargo, Inc. (included in the Schedule 14A filed on January 16, 2024, and incorporated herein by reference) (the “Definitive Proxy Statement”).
    (a)(2)(ii)
    ​
    ​
    Form of Proxy Card (included in the Definitive Proxy Statement and incorporated herein by reference).
    (a)(2)(iii)
    ​
    ​
    Letter to Stockholders (included in the Definitive Proxy Statement and incorporated herein by reference).
    (a)(2)(iv)
    ​
    ​
    Notice of Special Meeting of Stockholders (included in the Definitive Proxy Statement and incorporated herein by reference).
    (a)(2)(v)
        E-mail to Employees, dated December 1, 2023 (incorporated by reference to Eargo, Inc.’s Form DEFA14A (filed December 1, 2023) (File No.  001-39616)).
    (a)(2)(vi)     Definitive Additional Materials to the Proxy Statement of Eargo, Inc. (included in the Schedule 14A filed on February 7, 2024, and incorporated herein by reference).
    (a)(3)
        Press Release, dated February 16, 2024 (incorporated by reference to Exhibit 99.1 to Eargo Inc.’s Form 8-K (filed February 16, 2024) (File No. 001-39616)).
    (a)(5)(i)
    ​
    ​
    Press Release, dated October 30, 2023 (incorporated by reference to Exhibit 99.1 to Eargo, Inc.’s Form 8-K (filed October 30, 2023) (File No. 001-39616)).
    (a)(5)(ii)
    ​
    ​
    August 2023 Presentation (incorporated by reference to Exhibit 99.1 to Eargo, Inc.’s Form 8-K (filed August 10, 2023) (File No. 001-39616)).
    (c)(i)
    ​
    ​
    Opinion of Perella Weinberg Partners LP, dated October 29, 2023 (included as Annex C to the Definitive Proxy Statement, and incorporated herein by reference).
    (c)(ii)*
    ​
    ​
    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 19, 2023.
    (c)(iii)*
    ​
    ​
    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 28, 2023.
    (c)(iv)*
       
    The Presentation of Perella Weinberg Partners LP to the Special Committee, dated October 29, 2023.
    (d)(i)
    ​
    ​
    Agreement and Plan of Merger, dated October 29, 2023 by and among Eargo, Inc., PSC Echo Parent LLC and PSC Echo Merger Sub Inc. (included as Annex A to the Definitive Proxy Statement, and incorporated herein by reference).
    (d)(ii)
    ​
    ​
    Voting and Support Agreement, dated as of October 29, 2023, by and among Eargo, Inc. and PSC Echo, LP (included as Annex B to the Definitive Proxy Statement, and incorporated herein by reference).
    (f)
    ​
    ​
    Section 262 of the DGCL (included as Annex D to the Definitive Proxy Statement, and incorporated herein by reference).
    (g)
    ​
    ​
    Not Applicable.
    107*
    ​
    ​
    Filing Fee Table.

    * Previously Filed

    ​SIGNATURES

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EARGO, INC.
       
     
    By:
    /s/ William Brownie
     
     
    Name:  William Brownie
     
     
    Title:     Interim Chief Executive Officer and Chief Operating Officer

    Date: February 16, 2024


    ​ After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO PARENT LLC
       
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: February 16, 2024


    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO MERGER SUB INC.
       
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: February 16, 2024


    ​ After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO, LP
       
     
    By: PSC Echo GP, LLC, its general partner
     
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: February 16, 2024


    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PSC ECHO GP, LLC
       
     
    By:
    /s/ Adam Fliss
     
     
    Name: Adam Fliss
     
     
    Title:  Vice President

    Date: February 16, 2024


    Get the next $EAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EAR

    DatePrice TargetRatingAnalyst
    9/23/2021Outperform → Mkt Perform
    William Blair
    9/23/2021$11.00Overweight → Underweight
    JP Morgan
    9/23/2021$10.00Overweight → Equal-Weight
    Wells Fargo
    More analyst ratings

    $EAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:03:54 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Narula Onkarr

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 6:01:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Eargo, Inc. (0001719395) (Issuer)

      2/20/24 5:59:27 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Eargo Inc.

      15-12G - Eargo, Inc. (0001719395) (Filer)

      2/26/24 1:39:45 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:18 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Eargo Inc.

      S-8 POS - Eargo, Inc. (0001719395) (Filer)

      2/21/24 12:44:16 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      2/16/24 11:30:56 AM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Eargo Inc. (Amendment)

      SC 13D/A - Eargo, Inc. (0001719395) (Subject)

      10/30/23 5:21:26 PM ET
      $EAR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Eargo Inc. (Amendment)

      SC 13G/A - Eargo, Inc. (0001719395) (Subject)

      1/6/23 11:49:44 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Eargo Appoints Katie Bayne to Board of Directors

      SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos

      6/10/21 4:30:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

      SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1

      1/31/24 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

      SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th

      11/1/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

      SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues

      10/26/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eargo downgraded by William Blair

      William Blair downgraded Eargo from Outperform to Mkt Perform

      9/23/21 7:17:15 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by JP Morgan with a new price target

      JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00

      9/23/21 5:05:21 AM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00

      9/23/21 5:03:59 AM ET
      $EAR
      Medical Specialities
      Health Care

    $EAR
    Financials

    Live finance-specific insights

    See more
    • Eargo Reports Second Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will

      8/10/23 4:05:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo Reports First Quarter 2023 Financial Results

      Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported

      5/11/23 4:01:00 PM ET
      $EAR
      Medical Specialities
      Health Care
    • Eargo to Report First Quarter 2023 Financial Results on May 11, 2023

      SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s

      5/4/23 8:00:00 AM ET
      $EAR
      Medical Specialities
      Health Care